ASCO - Breast Cancer Biomarkers Flipbook

Biomarkers in Early Breast Cancer

ASCO Breast Cancer Biomarkers GUIDELINES App

Issue link: https://eguideline.guidelinecentral.com/i/848809

Contents of this Issue

Navigation

Page 6 of 7

Table 1. Breast Cancer Biomarkers to Guide Adjuvant Therapy Test ER/PgR-positive, HER2-negative (node-negative) ER/PgR-positive, HER2-negative (node-positive) HER2-positive or TN Oncotype DX Yes No No Endopredict Yes No No MammaPrint Yes a Yes b No Pam50 Yes No No Mammostrat No No No Breast Cancer Index Yes No No IHC4 No No No Urokinase plasminogen activator and plasminogen activator inhibitor type 1 Yes – No Circulating Tumor Cells No No No Tumor-Infiltrating Lymphocytes No No No Protein Encoded Mk167 Gene No No No a In patients with high clinical risk per MINDACT categorization. b In patients with 1–3 positive nodes and high clinical risk per MINDACT categorization.

Articles in this issue

view archives of ASCO - Breast Cancer Biomarkers Flipbook - Biomarkers in Early Breast Cancer